Clinical Trials · NCT06948435
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 487
- Start date
- Apr 2025
- Locations
- 99 sites, 11 countries
- Primary endpoint
- Change from Baseline in office Systolic Blood Pressure (SBP)